Taiho Oncology, Inc., a division of Taiho Pharmaceutical Co., Ltd. and Otsuka Holdings Co., Ltd., has built a world class clinical development organization that works urgently to develop innovative cancer treatments. Taiho has an oral oncology pipeline consisting of both novel antimetabolic agents and selectively targeted agents. Advanced technology, dedicated researchers, and state of the art facilities are helping us to define the way the world treats cancer. Taiho Oncology is committed to making products successfully developed and approved for marketing, commercially available to cancer patients in need. It’s our work; it’s our passion; it’s our legacy.
For more information about Taiho Oncology, please visit: www.taihooncology.comPatient Assistance Program Info